This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Oral etopside in oncology: An evolving role
Annals of Oncology. 1992 ;3(SUPPL. 3) :63-67
AbstractEtoposide has been in clinical trials for over 2 decades. From the inception of these investigations, both the oral and intravenous routes have been employed. The oral route has been shown to be convenient, safe, and effective in the trials of diseases such as small cell lung cancer and lymphomas. A recent resurgence of interest has surfaced with its oral application in the elderly and in protracted dosing schedules. Investigations are now under way assessing the relative value of the protracted oral dosing schema in a variety of diseases.
Notes09237534 (ISSN) Cited By: 2; Export Date: 31 May 2006; Source: Scopus CODEN: ANONE Language of Original Document: English Correspondence Address: Comis, R.L.; Fox Chase Cancer Center; 7701 Burholme Ave. Philadelphia, PA 19111, United States Chemicals/CAS: cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; cyclophosphamide, 50-18-0; doxorubicin, 23214-92-8, 25316-40-9; etoposide, 33419-42-0; ifosfamide, 3778-73-2; lomustine, 13010-47-4; methotrexate, 15475-56-6, 59-05-2, 7413-34-5; vincristine, 57-22-7, Etoposide, 33419-42-0Tradenames: vp 16 213